OncoMatch/Clinical Trials/NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Is NCT06528301 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies rapamycin for lymphoma, b-cell.
Treatment: rapamycin — This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 expression
Patients who have previously received CD19-directed therapy must have biopsy confirming CD19 expression following completion of prior CD19-directed therapy.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic bone marrow transplant
Cannot have received: gene therapy
Cannot have received: adoptive cell transfer
Exception: car t-cell therapy in car t-exposed subjects
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- The David and Etta Jonas Center for Cellular Therapy · Chicago, Illinois
- Washington University School of Medicine/Siteman Cancer Center · St Louis, Missouri
- University of Nebraska Medical Center · Omaha, Nebraska
- University of Cincinnatti Medical Center · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify